News - Sandoz, Financial

Filter

Current filters:

SandozFinancial

Popular Filters

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Novartis beats forecasts, despite generic and currency hits

19-07-2012

Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion,…

AlconFinancialGenericsNovartisPharmaceuticalSandoz

Novartis financials in line with expectations

25-01-2012

Swiss drug major Novartis (NOVN: VX) posted fourth quarter and full-year 2011 financial results this…

FinancialNovartisPharmaceuticalSandoz

Back to top